Skip to main content
Equibles
CRVO logo

CRVO · CervoMed Inc.

Track CRVO — free

Use CRVO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRVO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.31 +0.00 (+0.00%)
Rebalance outlook locked
Going-concern doubt — cleared Aug 7, 2026

The latest filing no longer states the doubt (first flagged May 15, 2026).

View the 10-Q filed Aug 7, 2026
Market Cap
$34.93M
Shares
15.12M
Volume · Oct 20 133.34K Avg daily vol (3M) 292.1K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.29 Open$2.28 Day$2.28–2.41 52W close$2.24–9.94 Avg vol 30d261K Short int1.3M · 8.9% float · 7.1d Short vol60% Last earningsJun 15, 2026 DataJan 2020–Oct 2026 Filing10-Q · Aug 7

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 2 wks
Latest filing: 10-Q
filed Aug 7, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$331,295
Trailing 12 months
Net income (TTM)
−$30.35M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-9,407.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+131.0%
Year over year · more shares
Price change (1Y)
-67.4%
Trailing year
Short interest
8.9%
Latest settlement · 7.1 days to cover
View all 122 metrics

Quarterly results

Revenue Net income Net loss
▲27.1% $1.94M −$4.75M '24 Q3 ▼13.2% $2.16M −$6.71M '24 Q4* ▼18.3% $1.92M −$4.89M '25 Q1 ▼46.6% $1.76M −$6.26M '25 Q2 ▼83.4% $322,569 −$7.73M '25 Q3 ▼99.6% $8,726 −$8.09M '25 Q4* ▼100% $0 −$7.96M '26 Q1 LATEST ▼100% $0 −$6.57M '26 Q2

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −39%
below
Price vs 50-day avg −14%
below
RSI (14) 38
neutral
MACD trend Negative
52-week position 1%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −9%
trailing
6-month return −37%
trailing
YTD return −71%
this year
Relative strength −45%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
2 of 37 funds reported for Sep 30 · net +7.3K sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.86% of float · ▲ +9.1% MoM · 7.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
37 holders — mid 3-yr range
Squeeze score 77
high risk · 0–100
Fundamentals
Weak
Revenue growth −59%
Y/Y
Gross margin 2%
expanding
EPS growth +5%
Y/Y
Free cash flow $-23.9M
Quant / Vol
risk profile
Very High
Volatility 116%
annualized · 1-yr
Max drawdown −77%
past year
ATR 9.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−39% Bearish
Price vs 50-day avg
−14% Bearish
RSI (14)
38 Neutral
MACD trend
Negative Bearish
52-week position
1% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
2 of 37 funds reported for Sep 30 · net +7.3K sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.86% of float · ▲ +9.1% MoM · 7.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
37 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $2 · 1% Range high $10
vs 200-day avg -39% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CRVO
CervoMed Inc.
this stock
$34.93M -71.0% -58.9% — 8.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
37
% held
11.6%
Reported
2 of 37
Top holder
Woodline Partners LP
Held Float
View
Held by Funds
Fund positions
10
View
Short & Settlement
Short Interest Rising
Shares short
1.3M
Days to cover
7.1d
Change
+111.9K sh
View
Short Volume
Short vol %
60%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
19.1K
Value
$48.5K
As of
Sep 28, 2026
View
Off-Exchange
Off-exchange %
46.2%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$4.0M
Net income (FY)
$-27.0M
EPS diluted
$3058336.50
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 14, 2026
This year
29

CervoMed Inc. made information concerning its business, clinical studies, development plans and financial position available on its website under “Investors – Events and Presentations,” for possible use in investor conferences, meetings and presentations.

View
Exempt Offerings
Offering
$750.0K
Filed
May 27, 2020
View
Earnings & Events
Webcasts
Last webcast
Aug 11, 2026
View
Investor Relations
Latest news
CervoMed Presents Initial Results…
Published
Oct 12, 2026
View

Performance

5D 20D 120D MTD YTD
CRVO +0.9% -9.5% -37.3% -22.9% -71.0%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY +2.0% -8.9% -45.3% -23.7% -83.8%
Key facts CIK 1053691 CUSIP 15713L109 13F (30d) 3 filings 3 filers Visit website Investor relations